Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorCHALOUNI, Mathieu
dc.contributor.authorRODRIGUEZ-CENTENO, J.
dc.contributor.authorSAMRI, A.
dc.contributor.authorBLANCO, J.
dc.contributor.authorSTELLA-ASCARIZ, N.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorWALLET, Cedrick
dc.contributor.authorKNOBEL, H.
dc.contributor.authorZUCMAN, D.
dc.contributor.authorALEJOS FERRERAS, B.
dc.contributor.authorAUTRAN, B.
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorTHIEBAUT, Rodolphe
dc.contributor.authorRAFFI, F.
dc.contributor.authorARRIBAS, J. R.
dc.date.accessioned2021-01-19T10:05:32Z
dc.date.available2021-01-19T10:05:32Z
dc.date.issued2020
dc.identifier.issn1932-6203en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/25866
dc.description.abstractEnIn 31 participants who started first-line antiretroviral therapy in the NEAT 001/ANRS 143 clinical trial, we found after 96 weeks a statistically significant increase in blood telomere length (TL) of 0.04 (T/S Ratio) (p = 0.03). This increase was positively correlated with both the change in the percentage of CD4+ T-cells and with the decrease of CD38+ molecules on Central Memory CD8+ and negatively correlated with the change in the percentage of CD4+ Effector Memory cells. Increase in TL could be an expression of immune reconstitution and the associated decrease in immune activation. We acknowledge for the low statistical power due to the small sample size and the potential for false positive results due to multiple testing. Hence, further studies are needed to confirm these observations.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subjectSISTM
dc.title.enCorrelation between blood telomere length and CD4+ CD8+ T-cell subsets changes 96 weeks after initiation of antiretroviral therapy in HIV-1-positive individuals
dc.title.alternativePLoS Oneen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1371/journal.pone.0230772
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed32267847en_US
bordeaux.journalPLoS ONEen_US
bordeaux.pagee0230772en_US
bordeaux.volume15en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue4en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamSISTM_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03160741
hal.version1
hal.date.transferred2021-03-23T09:57:25Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=PLoS%20ONE&rft.date=2020&rft.volume=15&rft.issue=4&rft.spage=e0230772&rft.epage=e0230772&rft.eissn=1932-6203&rft.issn=1932-6203&rft.au=CHALOUNI,%20Mathieu&RODRIGUEZ-CENTENO,%20J.&SAMRI,%20A.&BLANCO,%20J.&STELLA-ASCARIZ,%20N.&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée